NOVEL RADIOIMMUNOTHERAPY FOR OVARIAN CANCER

描述：（改编自研究者摘要） 该项目是为了优化腹膜炎患者的有效治疗， 使用区域放射免疫治疗参与卵巢癌。这些研究 将利用一种新设计的重组单克隆抗体， Ch2区（HuCC49 Ch2），用188Re放射性标记，并通过 腹腔内途径（IP）。他们先前使用177Lu-CC49进行的I期研究 显示出抗肿瘤作用的证据（客观反应和延长 无病生存），但试验受到免疫原性的限制。 鼠单克隆抗体和剂量限制性骨髓抑制。新 设计的分子应该具有很少或没有免疫原性， 治疗过程。此外，动物研究证实了预测的改善， 肿瘤穿透和血浆半衰期短，部分原因是由于小尺寸的 抗体构建体。该结构将用188 Re进行放射性标记， 在动物研究中显示出上级结果， 临床数据分析中的辐射。这种新的放射性标记产品 188Re-HuCC49 Ch2将成为可能，因为188Re可从发生器中获得 和一种稳定的三琥珀酸螯合剂，由他们的团队合成和测试。他们的 初始I期试验将确定最大耐受剂量（MTD），或 通过IP途径给予188Re-HuCC49 Ch2，包括免疫研究 反应、成像、剂量测定、药代动力学、肿瘤反应和肿瘤 标记。Donald Buchsbaum博士将同时分析重复给药方案 以及放射增敏剂在动物模型中的整合。动物模型 结果将用于后续临床试验的设计， 估计缓解率或进一步改善IP的抗肿瘤作用 188Re-HuCC49 Ch2的放射免疫治疗。这些研究将提供 有效的新疗法治疗卵巢癌患者复发后， 标准治疗或可能作为一线治疗的辅助策略。

DESCRIPTION: (adapted from the investigator's abstract) The purpose of this project is to optimize effective therapy for patients with peritoneal involvement of ovarian cancer using regional radioimmunotherapy. These studies will utilize a newly designed recombinant monoclonal antibody with a deleted Ch2 region (HuCC49 Ch2) radiolabeled with 188Re and administered by the intraperitoneal route (IP). Their prior phase I studies with 177Lu-CC49 have shown evidence of antitumor effects (objective responses and prolonged disease-free survival) but the trials were limited by the immunogenicity of the murine monoclonal antibody and dose-limiting marrow suppression. The newly designed molecule should have little or no immunogenicity allowing repeated courses of therapy. Also, animal studies have confirmed the predicted improved tumor penetration and short plasma half-life due, in part, to the small size of the antibody construct. The construct will be radiolabeled with 188Re, which has shown superior results in animal studies and is predicted to reduce marrow radiation in analysis of clinical data. This new radiolabeled product 188Re-HuCC49 Ch2 will be possible due to availability of 188Re from a generator and a stable trisuccin chelator synthesized and tested by their team. Their initial phase I trial will establish the maximum tolerated dose (MTD) or 188Re-HuCC49 Ch2 administered by IP route and include studies of immune response, imaging, dosimetry, pharmacokinetics, tumor response, and tumor markers. Dr. Donald Buchsbaum will concurrently analyze repeat dose schedules and integration of radiosensitizing agents in animal models. The animal model results will be utilized in the design of subsequent clinical trial aimed to estimate response rate or to further improve the antitumor effects of IP radioimmunotherapy with 188Re-HuCC49 Ch2. These studies should provide effective new therapy for ovarian cancer patients who have relapsed after standard therapy or possibly as an adjuvant strategy in first-line therapy.